Cytovation Overview

Founded 2001
Status Private
Employees 2
Latest Deal Type Angel
Latest Deal Amount $2.36M
Latest Deal Amount

Cytovation General Information


Operator of a biotech company intended to provide treatment of benign skin tumors. The company develops CyPep-1 is a first-in-class peptide with a novel mechanism of action, enabling patients to get treatment of benign skin tumours including cutaneous warts.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Primary Office
  • Møllendalsveien 65 C
  • 5009 Bergen
  • Norway
+47 55 00 00 00
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytovation Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Angel (individual) 29-Jun-2017 $2.36M 00.000 Completed Clinical Trials - Phase 1

Cytovation Executive Team (2)

Name Title Board Seat Contact Info
Kjell-Inge Arnevig Chief Executive Officer
Lars Prestegarden MD Co-Founder & Chief Scientific Officer

Cytovation Board Members (3)

Name Representing Role Since
Kristin Pundsnes Cytovation Board Member 000 0000
Per Lønning Ph.D Cytovation Chairman 000 0000
Rolf Bjerkvig Ph.D Cytovation Board Member 000 0000

Ready to get started?

Request a free trial